핵의학기술 (The Korean Journal of Nuclear Medicine Technology)

  • 제27권2호
  • /
  • Pages.83-93
  • /
  • 2023
  • /
  • 1229-9901(pISSN)
  • /
  • 2982-8406(eISSN)
대한핵의학기술학회 (The Korean Society of Nuclear Medicine Technology)
권호 표지
DOI QR코드

DOI QR Code

Synthesis of Novel 18F-Labeled-Nitroimidazole-Based Imaging Agents for Hypoxia: Recent Advances

  • Anh Thu Nguyen (Deparment of Nuclear Medicine, Jeonbuk National University) ;
  • Hee-Kwon Kim (Deparment of Nuclear Medicine, Jeonbuk National University)
  • 투고 : 2023.07.11
  • 심사 : 2023.08.01
  • 발행 : 2023.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Hypoxia indicates the condition of low oxygen levels in tissues. In oncology, hypoxia can induce cancer progression and metastasis, as well as cause resistance to cancer therapies. The detection of hypoxia by using molecular imaging, particularly, positron emission tomography (PET) has been extensively studied due to many advantages. Nitroimidazoles, the moieties that can be trapped in hypoxic tissues due to selective reduction, have been used to design and synthesize of hypoxia-targeting radiopharmaceuticals. This review provides a summary of synthetic routes towards 18F-labeled-nitroimidazole radiotracers for PET imaging of hypoxia.

키워드

참고문헌

  1. Weissleder R, Mahmood U. Molecular imaging. Radiology. 2001;219(2):316-33. https://doi.org/10.1148/radiology.219.2.r01ma19316
  2. Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. Clin Radiol. 2010;65(7):500-16. https://doi.org/10.1016/j.crad.2010.03.011
  3. Ollinger JM, Fessler JA. Positron Emission Tomography. IEEE Signal Process Magazine. 1997;14(1):43-55. https://doi.org/10.1109/79.560323
  4. Weber WA, Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel F, et al. The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. J Nucl Med. 2020;61(Suppl 2):263S-272S. https://doi.org/10.2967/jnumed.120.254532
  5. Lu FM, Yuan Z. PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases. Quant Imaging Med Surg. 2015;5(3):433-47.
  6. Unterrainer M, Eze C, Ilhan H, Marschner S, Roengvoraphoj O, Schmidt-Hegemann NS, et al. Recent advances of PET imaging in clinical radiation oncology. Radiat Oncol. 2020;15(1):88.
  7. Parker CC, Lapi SE. Positron Emission Tomography Imaging of Macrophages in Cancer. Cancers. 2021; 13(8):1921.
  8. Ma Y, Wang Q, Dong Q, Zhan L, Zhang J. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am J Cancer Res. 2019;9(8):1546-53.
  9. Li Y, Zhao L, Li XF. Hypoxia and the Tumor Microenvironment. Technol Cancer Res Treat. 2021;20:15330338211036304.
  10. Nejad AE, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M, et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021(1);21:62.
  11. Mittal S, Mallia MB. Molecular imaging of tumor hypoxia: Evolution of nitroimidazole radiopharmaceuticals and insights for future development. Bioorg Chem. 2023;139:106687.
  12. Jacobson O, Kiesewetter DO, Chen X. Fluorine-18 radiochemistry, labeling strategies and synthetic routes. Bioconjug Chem. 2015;26(1):1-18. https://doi.org/10.1021/bc500475e
  13. Wanek T, Kreis K, Krizkova P, Schweifer A, Denk C, Stanek J, et al. Synthesis and preclinical characterization of 1-(6'-deoxy-6'-[18F]fluoro-β-dallofuranosyl)-2-nitroimidazole (β-6'-[18F]FAZAL) as a positron emission tomography radiotracer to assess tumor hypoxia. Bioorg Med Chem. 2016;24(21):5326-39. https://doi.org/10.1016/j.bmc.2016.08.053
  14. Schweifer A, Hammerschmidt F. Preparation of Nucleosides Derived from 2-Nitroimidazole and d-Arabinose, d-Ribose, and d-Galactose by the Vorbruggen Method and Their Conversion to Potential Precursors for Tracers to Image Hypoxia. J Org Chem. 2011;76(20):8159-67. https://doi.org/10.1021/jo200727k
  15. Schweifer A, Maier F, Ehrlichmann W, Lamparter D, Kneilling M, Pichler BJ, et al. [18F]Fluoro-Azomycin-2'-Deoxy-β-D-Ribofuranoside - A New Imaging Agent for Tumor Hypoxia in Comparison with [18F]FAZA. Nucl Med Biol 2016;43(12):759-69. https://doi.org/10.1016/j.nucmedbio.2016.08.005
  16. Maier FC, Schweifer A, Damaraju VL, Cass CE, Bowden GD, et al. 2-Nitroimidazole-Furanoside Derivatives for Hypoxia Imaging-Investigation of Nucleoside Transporter Interaction, 18F-Labeling and Preclinical PET Imaging. Pharmaceuticals 2019:12(1):31.
  17. Kumar P, Ohkura K, Beiki D, Wiebe LI, Seki KI. Synthesis of 1-β-D-(5-Deoxy-5-Iodoarabinofuranosyl)-2-Nitroimidazole (β-IAZA): A Novel Marker of Tissue Hypoxia. Chem Pharm Bull. 2003;51(4):399-403. https://doi.org/10.1248/cpb.51.399
  18. Yang X, Wang F, Zhu H, Yang Z, Chu T. Synthesis and Bioevaluation of Novel [18F]FDG-Conjugated 2-Nitroimidazole Derivatives for Tumor Hypoxia Imaging. Mol Pharm. 2019;16(5):2118-28. https://doi.org/10.1021/acs.molpharmaceut.9b00075
  19. Cao J, Liu Y, Zhang L, Du F, Ci Y, Zhang Y, et al. Synthesis of Novel PEG-Modified Nitroimidazole Derivatives via "Hot-Click" Reaction and Their Biological Evaluation as Potential PET Imaging Agent for Tumors. J Radioanal Nucl Chem. 2017;312(2):263-76. https://doi.org/10.1007/s10967-017-5210-5
  20. Wang L, Wang H, Shen K, Park H, Zhang T, Wu X, et al. Development of Novel 18F-PET Agents for Tumor Hypoxia Imaging. J Med Chem. 2021;64(9):5593-602. https://doi.org/10.1021/acs.jmedchem.0c01962
  21. Nario AP, Woodfield J, Dos Santos SN, Bergman C, Wuest M, Araujo YB, et al. Synthesis of a 2-nitroimidazole derivative N-(4-[18F]fluorobenzyl)-2-(2-nitro-1H-imidazol-1-yl)-acetamide ([18F]FBNA) as PET radiotracer for imaging tumor hypoxia. EJNMMI Radiopharm Chem. 2022;7(1):13.
  22. Way J, Wuest F. Fully automated synthesis of 4-[18F]fluorobenzylamine based on borohydride/NiCl2 reduction. Nucl Med Biol. 2013;40(3):430-6. https://doi.org/10.1016/j.nucmedbio.2012.11.010
  23. Nunes PSG, Zhang Z, Kuo HT, Zhang C, Rousseau J, Rousseau E, et al. Synthesis and Evaluation of an 18F-Labeled Trifluoroborate Derivative of 2-Nitroimidazole for Imaging Tumor Hypoxia with Positron Emission Tomography. J Label Compd Radiopharm. 2018;61(4):370-9. https://doi.org/10.1002/jlcr.3594
  24. Lu J, Zhang C, Yang X, Yao XJ, Zhang Q, Sun XC. Synthesis and Preliminary Evaluation of a Novel 18F-Labeled 2-Nitroimidazole Derivative for Hypoxia Imaging. Front Oncol. 2021;10:1-9.  https://doi.org/10.3389/fonc.2020.572097